Literature DB >> 8624085

Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques.

M Hüll1, M Berger, B Volk, J Bauer.   

Abstract

Interleukin-6 (IL-6) immunoreactivity has previously been shown in plaques in Alzheimer's disease (AD), and elevated IL-6 concentrations have been measured biochemically in brains of AD patients. In this report, we present data on the appearance of IL-6 immunoreactivity in AD plaques according to the stage of plaque formation. Diffuse plaques are found in the early stages of plaque formation, whereas primitive and classic plaques are thought to represent later stages of plaque pathology. We classified plaques using the Bielschowsky silver stain method in serial sections of paraffin-embedded cortices of clinically diagnosed and histopathologically confirmed AD patients and patients with no clinical history of dementia. In the brains of nondemented and demented persons, we found plaques using the silver staining method or immunohistochemistry with antibodies against the amyloid precursor protein. In the nondemented group, diffuse plaques were the predominant plaque type, whereas primitive plaques formed the larger proportion of lesions in the group of AD brains. IL-6 was only detectable in plaques of demented patients. In AD cases, IL-6 was found in a significantly higher ratio in diffuse plaques as would have been expected from a random distribution of IL-6 in all plaque types. We conclude that the presence of IL-6 immunoreactivity correlates with clinically detectable dementia. In addition to the ubiquitous presence of amyloid in nondemented and demented brains, an IL-6-related immunological mechanism may be involved both in the transformation from diffuse to primitive plaques in AD and in the development of dementia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624085     DOI: 10.1111/j.1749-6632.1996.tb34420.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  15 in total

Review 1.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

Review 2.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

Review 3.  The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ.

Authors:  Cong Zheng; Xin-Wen Zhou; Jian-Zhi Wang
Journal:  Transl Neurodegener       Date:  2016-04-05       Impact factor: 8.014

Review 4.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

Review 5.  Sleep Disturbance and Alzheimer's Disease: The Glial Connection.

Authors:  Aditya Sunkaria; Supriya Bhardwaj
Journal:  Neurochem Res       Date:  2022-03-18       Impact factor: 3.996

6.  Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NFκB pathway signaling targets in LPS/IFNγ -activated BV-2 microglia cells.

Authors:  Makini K Cobourne-Duval; Equar Taka; Patricia Mendonca; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2018-05-04       Impact factor: 3.478

Review 7.  Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors.

Authors:  Mariana F Uchoa; V Alexandra Moser; Christian J Pike
Journal:  Front Neuroendocrinol       Date:  2016-09-17       Impact factor: 8.606

8.  Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults.

Authors:  Daniel S Albrecht; Abhay Sagare; Maricarmen Pachicano; Melanie D Sweeney; Arthur Toga; Berislav Zlokovic; Helena Chui; Elizabeth Joe; Lon Schneider; John C Morris; Tammie Benzinger; Judy Pa
Journal:  Brain Behav Immun       Date:  2021-01-22       Impact factor: 7.217

9.  A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment.

Authors:  Li Liu; Ian J Orozco; Emmanuel Planel; Yi Wen; Alexis Bretteville; Pavan Krishnamurthy; Lili Wang; Mathieu Herman; Helen Figueroa; W Haung Yu; Ottavio Arancio; Karen Duff
Journal:  Neurobiol Dis       Date:  2008-04-07       Impact factor: 5.996

10.  Inflammatory process in Alzheimer's Disease.

Authors:  Marco A Meraz-Ríos; Danira Toral-Rios; Diana Franco-Bocanegra; Juana Villeda-Hernández; Victoria Campos-Peña
Journal:  Front Integr Neurosci       Date:  2013-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.